Quarterly ResultAug 6, 2026, 07:05 AM
Ocugen Gets FDA Phase 3 Clearance for OCU410, RMAT; Secures $130M
AI Summary
Ocugen reported Q2 2026 financial results, alongside significant clinical and corporate advancements. The company received FDA clearance to initiate the OCU410 Phase 3 trial for geographic atrophy and was granted Regenerative Medicine Advanced Therapy (RMAT) designation, enabling priority review. Ocugen also secured $130.0 million in convertible senior notes financing, extending its cash runway into 2028, and signed a binding term sheet for an exclusive OCU400 license in the MENA region. The company reported a net loss of $0.07 per share for the quarter.
Key Highlights
- FDA cleared OCU410 Phase 3 trial for geographic atrophy; RMAT designation granted.
- Secured $130.0 million in convertible senior notes financing, extending cash runway into 2028.
- Signed binding term sheet for OCU400 license in MENA, with up to $255 million in sales milestones.
- OCU400 Process Performance Qualification (PPQ) batches successfully completed.
- OCU410ST Phase 2/3 trial enrollment completed ahead of schedule with 63 subjects.
- Cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026.
- Net loss per common share was $0.07 for the three months ended June 30, 2026.
- Total operating expenses for Q2 2026 were $17.9 million.
Price Impact
More from OCGN